151 related articles for article (PubMed ID: 36517084)
41. Outcomes of prophylactic cranial irradiation in patients with small cell lung cancer in the modern era of baseline magnetic resonance imaging of the brain.
Held MK; Hansen O; Schytte T; Hansen KH; Bahij R; Nielsen M; Nielsen TB; Jeppesen SS
Acta Oncol; 2022 Feb; 61(2):185-192. PubMed ID: 34583620
[TBL] [Abstract][Full Text] [Related]
42. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
43. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry.
Tsimafeyeu I; Zolotareva T; Varlamov S; Zukov R; Petkau V; Mazhbich M; Statsenko G; Safina S; Zaitsev I; Sakaeva D; Popov A; Borisov P; Vladimirova L
Clin Genitourin Cancer; 2017 Dec; 15(6):e1069-e1072. PubMed ID: 28882737
[TBL] [Abstract][Full Text] [Related]
44. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.
Peverelli G; Raimondi A; Ratta R; Verzoni E; Bregni M; Cortesi E; Cartenì G; Fornarini G; Facchini G; Buti S; Galli L; Tucci M; Prisciandaro M; Procopio G
Clin Genitourin Cancer; 2019 Aug; 17(4):291-298. PubMed ID: 31178240
[TBL] [Abstract][Full Text] [Related]
45. Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
Sperduto PW; Deegan BJ; Li J; Jethwa KR; Brown PD; Lockney N; Beal K; Rana NG; Attia A; Tseng CL; Sahgal A; Shanley R; Sperduto WA; Lou E; Zahra A; Buatti JM; Yu JB; Chiang V; Molitoris JK; Masucci L; Roberge D; Shi DD; Shih HA; Olson A; Kirkpatrick JP; Braunstein S; Sneed P; Mehta MP
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):845-853. PubMed ID: 29976497
[TBL] [Abstract][Full Text] [Related]
46. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.
Schutz FA; Xie W; Donskov F; Sircar M; McDermott DF; Rini BI; Agarwal N; Pal SK; Srinivas S; Kollmannsberger C; North SA; Wood LA; Vaishampayan U; Tan MH; Mackenzie MJ; Lee JL; Rha SY; Yuasa T; Heng DY; Choueiri TK
Eur Urol; 2014 Apr; 65(4):723-30. PubMed ID: 24184025
[TBL] [Abstract][Full Text] [Related]
47. Clinical outcomes of 168 Chinese patients after local surgery for bone metastases arising from advanced renal cell carcinoma.
Dong Y; Wang Z; Lu X; Wu Z; Zhang Z; Yu Y; Peng F; Liu B; Wang L
Cancer; 2020 May; 126 Suppl 9():2079-2085. PubMed ID: 32293722
[TBL] [Abstract][Full Text] [Related]
48. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
49. Patterns of care for metastatic renal cell carcinoma in Australia.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Andrews M; Davis ID; Azad AA; Rosenthal M; Wong S; Johnstone A; Gibbs P; Tran B
BJU Int; 2015 Oct; 116 Suppl 3():36-41. PubMed ID: 26204961
[TBL] [Abstract][Full Text] [Related]
50. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
51. Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases.
Nieder C; Dalhaug A; Pawinski AR
In Vivo; 2020; 34(2):675-678. PubMed ID: 32111768
[TBL] [Abstract][Full Text] [Related]
52. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
[TBL] [Abstract][Full Text] [Related]
53. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
54. Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations.
Lindskog M; Wahlgren T; Sandin R; Kowalski J; Jakobsson M; Lundstam S; Ljungberg B; Harmenberg U
Urol Oncol; 2017 Sep; 35(9):541.e15-541.e22. PubMed ID: 28623071
[TBL] [Abstract][Full Text] [Related]
55. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
[TBL] [Abstract][Full Text] [Related]
56. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
57. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
Harrison MR; Costello BA; Bhavsar NA; Vaishampayan U; Pal SK; Zakharia Y; Jim HSL; Fishman MN; Molina AM; Kyriakopoulos CE; Tsao CK; Appleman LJ; Gartrell BA; Hussain A; Stadler WM; Agarwal N; Pachynski RK; Hutson TE; Hammers HJ; Ryan CW; Inman BA; Mardekian J; Borham A; George DJ
Cancer; 2021 Jul; 127(13):2204-2212. PubMed ID: 33765337
[TBL] [Abstract][Full Text] [Related]
58. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
Brown LC; Desai K; Wei W; Kinsey EN; Kao C; George DJ; Rini BI; Ornstein MC; Zhang T
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518292
[TBL] [Abstract][Full Text] [Related]
59. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
Lee HW
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
[TBL] [Abstract][Full Text] [Related]
60. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
